학술논문
Reply to Correspondence on "Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase".
Document Type
Article
Author
Source
Subject
*PROTEIN-tyrosine kinase inhibitors
*LIGANDS (Chemistry)
*
Language
ISSN
0044-8249
Abstract
At pharmacologically relevant concentrations, asciminib and clinical adenosine triphosphate (ATP) kinase inhibitors cannot simultaneously bind to Abl kinase. Manley and co‐workers correspond that at saturating concentrations (i.e., concentrations that are not achievable in a human), asciminib and dasatinib can simultaneously bind to Abl kinase. [ABSTRACT FROM AUTHOR]